Sweden · Delayed Price · Currency is SEK Theseus Pharmaceuticals Statistics
Total Valuation
SpectraCure AB has a market cap or net worth of SEK 15.02 million. The enterprise value is 11.50 million.
| Market Cap | 15.02M |
| Enterprise Value | 11.50M |
Important Dates
The next estimated earnings date is Friday, August 15, 2025.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SpectraCure AB has 97.13 million shares outstanding.
| Current Share Class | 97.13M |
| Shares Outstanding | 97.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.74% |
| Owned by Institutions (%) | 12.92% |
| Float | 81.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.15 |
| P/TBV Ratio | 0.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.49 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.50 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.04 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -50.41 |
Financial Efficiency
Return on equity (ROE) is -20.80% and return on invested capital (ROIC) is -12.55%.
| Return on Equity (ROE) | -20.80% |
| Return on Assets (ROA) | -11.50% |
| Return on Invested Capital (ROIC) | -12.55% |
| Return on Capital Employed (ROCE) | -23.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.79M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.25% in the last 52 weeks. The beta is 0.36, so SpectraCure AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -93.25% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 1.46 |
| Relative Strength Index (RSI) | 33.23 |
| Average Volume (20 Days) | 2,723,632 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | 9.69M |
| Operating Income | -23.64M |
| Pretax Income | -23.34M |
| Net Income | -23.33M |
| EBITDA | -23.26M |
| EBIT | -23.64M |
| Earnings Per Share (EPS) | -0.24 |
Balance Sheet
The company has 8.09 million in cash and 4.58 million in debt, giving a net cash position of 3.51 million or 0.04 per share.
| Cash & Cash Equivalents | 8.09M |
| Total Debt | 4.58M |
| Net Cash | 3.51M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 100.54M |
| Book Value Per Share | 1.04 |
| Working Capital | 479,000 |
Cash Flow
In the last 12 months, operating cash flow was -22.97 million and capital expenditures -98,000, giving a free cash flow of -23.07 million.
| Operating Cash Flow | -22.97M |
| Capital Expenditures | -98,000 |
| Free Cash Flow | -23.07M |
| FCF Per Share | -0.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SpectraCure AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -155.39% |
| FCF Yield | -153.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |